China’s Next Wave of Innovation: 10 Breakthrough Drugs to Watch in H2 2026
The 10 breakthrough drugs to watch in H2 2026 in China span a wide range of therapeutic areas, including oncology,
2026-08-26
Innovative Drug News
HER2 Bispecific Antibody Meets China’s PD-1: FDA Approves Ziihera Plus Tislelizumab Combination Therapy
HER2 Bispecific Antibody Meets China’s PD-1: In August 2026, the U.S. Food and Drug Administration (FDA) approved two first-line treatment
2026-08-27
A New Weapon for Psoriasis Treatment | How Icotrokinra Is Advancing Psoriasis Care into the Era of Precision Treatment
On August 27, 2026, a major milestone was reached in the field of psoriasis treatment in China. Johnson & Johnson
2026-08-28
Long-Acting RSV Monoclonal Antibodies Mark a New Breakthrough: XinDuoTuo® and YingMuLe® Approved on the Same Day, Offering New Options for RSV Prevention in Infants
New breakthrough in long-acting RSV monoclonal antibodies: XinDuoTuo® and YingMuLe® approved on the same day. On September 3, 2026, China’s
2026-09-05
What Is Redemplo®? The World-First APOC3 siRNA Therapy for Precision Treatment of Familial Chylomicronemia Syndrome
What Is Redemplo? As the world-first APOC3 siRNA therapy, Redemplo® represents a significant advancement in RNA interference (RNAi)-based precision medicine
2026-07-24
Sacituzumab Tirumotecan Advances to Frontline Therapy: New Indication Application Accepted for Triple-Negative Breast Cancer
In recent years, Antibody-Drug Conjugates (ADCs) have emerged as one of the fastest-growing classes of innovative cancer therapies, combining the
2026-07-30
AiWeiDa® Approved for New Indication HER2-Positive Colorectal Cancer: A New Option for Precision Treatment
In recent years, Antibody-Drug Conjugates (ADCs) have continued to drive advances in precision oncology, gradually becoming one of the most
2026-08-07
Enhertu® Plus Pertuzumab Approved in China: A New ADC-Based First-Line Treatment for HER2-Positive Metastatic Breast Cancer
On August 11, 2026, Enhertu® (generic name: trastuzumab deruxtecan, T-DXd) in combination with Pertuzumab was approved in China for the
2026-08-12
What Is Tezepelumab Injection? Tezspire Approved and Launched in China, Offering a New Treatment Option for Severe Asthma and CRSwNP
Tezepelumab Injection is a targeted biologic therapy that blocks TSLP to help control airway inflammation. On August 17, 2026, AstraZeneca
2026-08-20
